ADVERTISEMENT

ADVERTISEMENT

American Opinion: Feds need to ramp up COVID treatment

Summary: The administration needs to commit enough resources to enroll more providers and to make the application process more reliable and convenient. Putting treatments directly into the hands of those infected with COVID-19 is smart strategy, and early intervention could spare some Americans from longer-term health complications. But the federal government needs to get this right, and then use the program to its full potential.

SureCare Pharmacy manager Oscar Uribe shows off a package of Pfizer Paxlovid pills inside of Esperanza Health Center in Chicago's Brighton Park neighborhood on Jan. 13, 2022. Pfizer's Paxlovid is a treatment for COVID-19.
SureCare Pharmacy manager Oscar Uribe shows off a package of Pfizer Paxlovid pills inside of Esperanza Health Center in Chicago's Brighton Park neighborhood on Jan. 13, 2022. Pfizer's Paxlovid is a treatment for COVID-19.
Chris Sweda/Chicago Tribune/TNS
We are part of The Trust Project.

The nation’s response to the pandemic has taken on a new phase, as mask mandates and social distancing give way to home-based testing and outpatient treatments. That’s why it’s essential the Biden administration get its new “test-to-treat” program up to speed. With new infections rising in Florida and nationally, the program is vital for helping a fatigued nation manage this ongoing outbreak.

The program, announced in March , is meant to control COVID-19 hospitalizations and deaths by providing antiviral pills on the spot to people who test positive for the virus. It’s another step in the government’s evolution of making individuals more involved in the nation’s response. As a recent report by Kaiser Health News explains , Pfizer’s Paxlovid and Merck’s Lagevrio are both designed to be started within five days of symptoms appearing. Millions of chronically ill and older Americans are eligible, and more people may qualify soon, but many Americans don’t have access to the program. It’s ridiculous that cost and bureaucratic hurdles are still undermining this public health effort more than two years after COVID-19 exploded on the scene.

American Opinion
American Opinion

As envisioned, the program allows people with COVID-19 symptoms to get tested, be prescribed antiviral pills and fill the prescription in a single visit. The federal government and many state and local health departments direct residents to an online national map of test-to-treat sites. But as of two weeks ago, large swaths of the country had no test-to-treat pharmacies or health centers listed, according to a Kaiser survey. The program’s largest participant, CVS, had technical issues that made booking an appointment difficult. The roll out has exposed America’s fragmented public health system, where the federal, state and local governments all play a role. And it shows how high, upfront costs are barriers to keeping people healthy and hospitals operating as normal.

The federal government has set aside nearly 400,000 courses of the antivirals for its federal pharmacy partners — about a quarter of the total supply since the program began, according to Kaiser. Although the cost of the pills is covered by the federal government, obtaining a prescription at participating pharmacies can be expensive, upwards of $100 for exam appointments. Kaiser also found that finding treatment might be impossible. While CVS said it is working to fix a software glitch affecting in-person appointments, some Americans, especially seniors, may lack the equipment or skills for telehealth visits. And many rural communities that lack doctors, clinics and pharmacies are underserved, forcing people to drive long distances for hours to participate.

This is unacceptable. The nation is rightly moving away from top-down restrictions on masks and movement. In-home tests and treatments are more widely available, reflecting how far America has come in its public health response. But a nimbler strategy depends on execution. With cases in Florida nearly doubling over the last two weeks, and new infections nationwide up 51%, the “test-to-treat” program is critical to curbing the spread and an unmanageable spike in hospitalizations.

ADVERTISEMENT

The administration needs to commit enough resources to enroll more providers and to make the application process more reliable and convenient. Putting treatments directly into the hands of those infected with COVID-19 is smart strategy, and early intervention could spare some Americans from longer-term health complications. But the federal government needs to get this right, and then use the program to its full potential.

This American Opinion editorial is the opinion of the editorial board of the Tampa Bay Times.

©2022 Tampa Bay Times. Visit tampabay.com . Distributed by Tribune Content Agency, LLC.

More editorials:
Recent editorials of other newspapers published in the West Central Tribune.
From the editorial: (Business) know that society has become more inclusive and tolerant in recent years. That’s what puts such a bitter taste in Tucker Carlson’s mouth.

Related Topics: CORONAVIRUSUNITED STATES
What To Read Next
From the editorial: The rules are the rules. It shouldn’t be too much to expect the country’s highest leaders to start following them.
From the editorial: The days of magnanimity and bipartisan compromise are over. Some people want war and seem determined to provoke it.
From the editorial: First, public debt cannot safely be allowed to keep rising at the projected rate. Second, purporting to solve this problem by threatening to default on the country’s obligations is nuts.
Why is it that women’s hygiene products are not offered for free in school bathrooms?